Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. The site will manufacture various types of rare disease drugs, including those for the treatment of haemophilia, Novo Nordisk said in a statement on Monday. The site will include a warehouse as well as a factory, it said.
Leave A Comment